Ionis’ Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results

This article was originally published here

IONIS-FXI-LRx utilizes Ionis’ advanced LIgand Conjugated Antisense (LICA) technology platform and is designed to reduce the production of Factor XI (FXI), a clotting factor produced in the liver.

The post Ionis’ Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply